SUDARSCHEM

- Trading window closed from July 1, 2026, until 48 hours after Q1 FY27 results announcement. - This is for Unaudited Financial Results for the quarter ended June 30, 2026. - Board Meeting date for approval will be communicated in due course.

- Concall Schedule - Concall Date: 29th June, 2026 - Concall Time: 11:30 A.M. (IST) - Meeting Type: In-person one-on-one with Axis Capital Limited.

- Concall Schedule - Concall Date: 30th June, 2026 - Concall Time: 10:30 A.M. (IST) - Meeting with: Aditya Birla Sunlife Mutual Fund (In-person one-on-one)

- Concall Schedule - Concall Date: 26th June, 2026 - Concall Time: 11:00 A.M. (IST)

- Intimation of an in-person meeting with Mahindra Manulife Mutual Fund. - Scheduled for June 18, 2026, at 09:00 A.M. (IST). - No Unpublished Price Sensitive Information will be discussed during the meeting.

- Chairman & MD, Rajesh Rathi, converted 9,80,000 warrants into equity shares at ₹1,019.75 each (16% premium to market price on June 10, 2026). - This action increased the promoter group holding from 8.19% to 9.32% and completed a capital commitment of close to ₹100 crore. - Mr. Rathi expressed strong confidence in the company's future and long-term commitment.

- Concall Schedule - Concall Date: 17th June, 2026 - Concall Time: 02:00 P.M. (IST) - Interaction with: Abakkus Diversified Alpha Fund via Video Conference (one-on-one Meeting)

- Sudarshan Chemical Industries inaugurated its second global head office in Frankfurt, Germany, on June 9, 2026. - The 21,000 sq ft office signifies post-acquisition growth ambitions and long-term commitment to Germany/Europe after the Heubach Group acquisition.

- Concall Schedule - Concall Date: 17th June, 2026 - Concall Time: 03:30 P.M. (IST)

- Sudarshan Chemical Industries allotted 9,80,000 equity shares to promoter Mr. Rajesh Balkrishna Rathi at ₹1,019.75 per share, upon conversion of warrants. This increased the paid-up equity capital and the promoter's stake from 8.19% to 9.32%.

- Sudarshan Chemical Industries Limited allotted 9,80,000 equity shares of face value ₹2/- each to Mr. Rajesh Balkrishna Rathi (promoter) upon conversion of warrants. - The promoter had paid the remaining 75% consideration of ₹74,95,13,800. - Post-allotment, the promoter's stake increased from 8.19% to 9.32%.

- Allotment of 9,80,000 Equity Shares to promoter Mr. Rajesh Balkrishna Rathi on June 10, 2026, upon conversion of warrants. - The remaining 75% consideration of ₹74.95 Cr was remitted. - Promoter's shareholding increased from 8.19% to 9.32% post-allotment.

- Q4 Performance (Acquired Group): Achieved Business EBITDA of Euro 11 million against a projection of Euro 9-10 million. - Inventory Reduction: Reduced inventory by Euro 29 million, exceeding the planned Euro 20 million reduction. - Net Debt: Group net debt reduced from INR934 crores (Dec '25) to INR755 crores (March '26), with a net debt-to-equity ratio of 0.3x. - RIECO FY26 Performance: Revenue grew 17.5% YoY to INR268 crores; EBITDA turned positive to INR10 crores from negative INR17 crores. - Integration & Synergies: Targeting EUR 90-100 million in synergies over 3-4 years; expecting EUR 35 million EBITDA from the acquired group in FY27. - Legacy Business Outlook: Projecting 8-10% volume growth for the current year (FY27) with maintained healthy margins. - Capacity & Growth: Sufficient capacity headroom in both legacy and acquired businesses to support future growth without significant new capital expenditure for volumes. - Operational Strategy: Actively passing on increased raw material, energy, and logistics costs to customers while leveraging global footprint and value capture initiatives. - Strategic Initiatives: Exploring disposal of non-core assets and progressing with One SAP Drive project Integra.

Standalone Revenue ₹732.7 Cr vs ₹703.6 Cr (▲4.1% YoY), EBITDA ₹157.0 Cr vs ₹59.9 Cr (▲162.1% YoY), PAT ₹120.4 Cr vs ₹22.4 Cr (▲437.5% YoY). EBITDA Margin expanded from 8.5% to 21.4% (▲1292bps). The board also recommended a final dividend of ₹5/- per equity share (250%) for the financial year 2025-26.

Standalone Revenue ₹732.7Cr vs ₹703.6Cr (▲4.1% YoY), EBITDA ₹157.0Cr vs ₹59.9Cr (▲162.1% YoY), PAT ₹120.4Cr vs ₹22.4Cr (▲437.5% YoY). EBITDA Margin 21.4% vs 8.5% (▲1292bps). The Board also recommended a final dividend of ₹5/- per equity share for FY 2025-26, and approved the appointment of Internal and Cost Auditors for FY 2026-27.

Consolidated Revenue ₹2,789.9Cr vs ₹1,349.4Cr (▲107% YoY), EBITDA ₹227.4Cr vs ₹127.0Cr (▲79% YoY), PAT ₹82.5Cr vs ₹0.4Cr (▲20525% YoY) for the quarter ended 31st March 2026. EBITDA Margin 8.15% vs 9.41% (▼126bps). The Board also recommended a final dividend of ₹5/- per equity share for FY26.

New Filing detected. See link for details.

On April 27, 2026, Sudarshan Chemical Industries Limited allotted 15,640 equity shares of face value Rs. 2/- each, at an exercise price of Rs. 349.35/-, to grantees who exercised options under the Employee Stock Option Plan 2018.